Patents by Inventor Øyvind S. Bruland

Øyvind S. Bruland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTIGEN BINDING UNITS FOR TARGETING OSTEOSARCOMA CELLS
    Publication number: 20230355672
    Abstract: Provided herein are proteins comprising a novel antigen binding domain. Said antigen binding domain, and proteins comprising it, are able to bind to osteosarcoma cells under physiological conditions. The antigen binding domain comprises an antibody light chain variable domain (VL) and an antibody heavy chain variable domain (VH), each comprising three complementarity determining regions (CDRs) flanked by human framework sequences. The human framework sequences reduces the risk of triggering unwanted immunogenic responses against the antigen binding domain. This may be especially important in a therapeutic setting wherein a drug is administered repeatedly to a human osteosarcoma patient.
    Type: Application
    Filed: June 24, 2021
    Publication date: November 9, 2023
    Inventors: Sébastian Wälchli, Øyvind S. Bruland, Darragh McCann, Samantha Crawford, Else Marit Inderberg, Monica Berrondo, Susana Kaufmann, Jacob Byerly
  • Chimeric Antigen Receptors (CARS) and Their Use in Medicine
    Publication number: 20220175897
    Abstract: Novel chimeric antigen receptors (CARs) are provided. When the CARs herein are expressed on the surface of immune cells, such immune cells may be directed to osteosarcoma cells as demonstrated with our in vivo data. In a murine intraperitoneal model, the tumor growth was significantly delayed for T cells expressing a CAR comprising a scFv from TP1 or TP3 antibodies. Immune cells expressing the CARs herein display therapeutic effect in the form of decreased tumor volume in a murine model simulating metastatic osteosarcoma. Combined with the finding that stem cells from healthy bone marrow were not significantly affected by T cells expressing any of the CARs, this disclosure provides an attractive cell therapeutic alternative for treatment of osteosarcoma.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 9, 2022
    Inventors: Else Marit Inderberg, Sébastian Wälchli, Øyvind S. Bruland
  • Radioimunoconjugates and uses thereof
    Patent number: 9358309
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer and in particular B cell malignancies are aspects of the present invention.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: June 7, 2016
    Assignee: Nordic Nanovector AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S. Bruland
  • RADIOIMMUNOCONJUGATES AND USES THEREOF
    Publication number: 20140147384
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer and in particular B cell malignancies are aspects of the present invention.
    Type: Application
    Filed: December 9, 2013
    Publication date: May 29, 2014
    Applicant: Nordic Nanovector AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S. Bruland
  • Radioimmunoconjugates and uses thereof
    Patent number: 8628749
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer—and in particular B-cell malignancies—are aspects of the present invention.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: January 14, 2014
    Assignee: Nordic Nanovector AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S Bruland
  • RADIOIMMUNOCONJUGATES AND USES THEREOF
    Publication number: 20120301396
    Abstract: The present invention relates to a radioimmunoconjugate that binds human CD37. Pharmaceutical compositions and uses thereof for the treatment of cancer—and in particular B-cell malignancies—are aspects of the present invention.
    Type: Application
    Filed: January 28, 2011
    Publication date: November 29, 2012
    Applicant: NORDIC NANOVECTOR AS
    Inventors: Roy H. Larsen, Jostein Dahle, Øyvind S. Bruland
  • Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
    Patent number: 6635234
    Abstract: Processes for the preparation, prepared solutions, and the use of radium-223 for the treatment of calcified tumors, bone tumors, treatment of bones, bone surfaces and soft tissues is described.
    Type: Grant
    Filed: January 3, 2000
    Date of Patent: October 21, 2003
    Assignee: Anticancer Therapeutic Inventions AS
    Inventors: Roy H. Larsen, Gjermund Henriksen, Øyvind S. Bruland